Navigation Links
Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB
Date:10/22/2007

ROCKVILLE, MD -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat diseases of epidemic potential, announced today that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) independently reviewed Sequella lead drug compound, SQ109, and both agencies granted SQ109 orphan drug status for the treatment of tuberculosis. SQ109 shows excellent in vitro and in vivo activity against drug-susceptible and drug-resistant TB bacteria, including XDR-TB. Further, SQ109 synergizes with other TB drugs in experimental animal models of TB, and could result in new TB drug combinations that have much greater activity than the current standard of care.

We are pleased that the FDA and the EMEA awarded Sequella orphan drug and orphan medicinal product status for the use of SQ109 (N-adamantany1-N-Geranyl-ehtylendiamine) for the treatment of tuberculosis (TB), a chronically debilitating and life-threatening infectious pulmonary and extrapulmonary disease, said Dr. Carol Nacy. With the resurgence of TB in a new drug-resistant form it is clear there is a need to readdress the treatment of this infectious and deadly disease. To accelerate our clinical programs, we will continue to work closely with the FDAs Office of Orphan Products Development and the EMEAs Committee for Orphan Medicinal Products as we move through the clinical and regulatory process.

The Orphan Drug Act (Public Law 97-414, enacted in 1983 and amended) provides for economic incentives to encourage pharmaceutical companies to develop drugs for rare diseases defined as those affecting fewer than 200,000 people in the United States. Orphan drug designation entitles Sequella, Inc. to seven years of market exclusivity for SQ109 for the treatment of patients with tuberculosis. Additional incentives for orphan drug development include tax credits related to certain development expenses, an exemption from the FDA user fee, and
'/>"/>

Contact: Alicia Moran
alicia@brightlinemedia.com
410-991-7027
Sequella
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. DuPonts first biologically derived polymer receives global recognition
2. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
3. Research on antibiotics receives historical recognition
4. Anthrax test, developed by army and CDC, receives FDA approval
5. Research team receives $7.5 million to study cassava
6. Virulizin granted orphan drug status in Europe
7. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
8. Sudden change in social status triggers genetic response in male fish, study finds
9. Gene expression test reveals ER and HER-2 status of breast tumors
10. MU researchers to study the status of black bears in Missouri
11. Protein discovery could unlock the secret to better TB treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... a room in the intensive care unit (ICU) ... may increase the odds of acquiring such bacteria, ... issue of Archives of Internal Medicine, one of ... significant illness and death in hospitals: methicillin-resistant Staphylococcus ...
... cold seeps--strange clams, mussels and sea snails that thrive in ... marine mollusk community as a whole, according to a new ... published by AAAS, the nonprofit science society. , On average, ... geological record is a full epoch earlier than that of ...
... Boston have demonstrated that it may be possible to ... the heart from scarring. Working with rats, they combined ... division with a naturally occurring growth factor that encourages ... heart-muscle cells to multiply and the heart to regain ...
Cached Biology News:Transmission of antibiotic-resistant bacteria linked to previous intensive care unit room occupants 2Ocean seep mollusks may share evolutionary history with other deep-sea creatures 2Ocean seep mollusks may share evolutionary history with other deep-sea creatures 3Rescuing injured hearts by enhancing regeneration 2Rescuing injured hearts by enhancing regeneration 3
(Date:4/21/2015)... April 21, 2015  Novogen Limited (ASX:NRT; NASDAQ: ... advises that it has entered into definitive agreements ... shares plus one attaching 6-month option and half ... share issued, to institutional investors in ... placement for aggregate gross proceeds of approximately AU$15,500,000 ...
(Date:4/21/2015)... PRC Clinical, a Clinical ... the ACRP 2015 Global Conference and Exhibition on April ... of Clinical Research Professionals (ACRP) Global Conference and Exhibition ... on the conduct of clinical trials. ACRP supports clinical ... recognized industry certifications. , The ACRP 2015 Global ...
(Date:4/21/2015)... RESEARCH TRIANGLE PARK, N.C. , April 21, 2015 ... announced today that it will release its first quarter ... 28, 2015. United Therapeutics will host a ... a.m. Eastern Time.  The teleconference is accessible by dialing ... the teleconference will be available for one week and ...
(Date:4/21/2015)... New York (PRWEB) April 21, 2015 ... and Fertility Authority, LLC, announced that it has secured ... Byers (KPCB), TPG Biotech, SR One and Merck Serono ... efforts to provide patients the best fertility outcomes by ... is the largest online marketplace for families seeking fertility ...
Breaking Biology Technology:Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2
... Holdings, Inc. (Nasdaq: NHWK ), the leading ... United States, today announced that,Tim Mayleben, NightHawk,s President ... for personal reasons. Mayleben will remain with,NightHawk in ... and is,expected to resign from the board of ...
... Martek Biosciences,(Nasdaq: MATK ) announced today that ... eye and heart health, is now available in,two new ... Grapefruit Lychee and Marionberry Guava, join 10 existing flavors ... line is,available at natural food stores nationwide., "We ...
... Board of Directors, Ron ... Vice President Legal Affairs -, SEATTLE, Feb. 13 ... development of therapeutics for,autoimmune and inflammatory disorders, today announced ... of Dendreon Corporation,(Nasdaq: DNDN ), to the Company,s ...
Cached Biology Technology:NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures 2NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures 3Martek's life'sDHA(TM) Now Featured in Two New Flavors of Rachel's(R) Wickedly Delicious Yogurt from WhiteWave Foods 2Martek's life'sDHA(TM) Now Featured in Two New Flavors of Rachel's(R) Wickedly Delicious Yogurt from WhiteWave Foods 3VLST Corporation Announces Board and Executive Management Appointments 2VLST Corporation Announces Board and Executive Management Appointments 3